Polyunsaturated fatty acids increase the sensitivity of 36B10 rat astrocytoma cells to radiation-induced cell kill.
Polyunsaturated fatty acids (PUFA) such as gamma-linolenic acid (GLA, 18:3n-6), eicosapentaenoic acid (EPA, 20:5n-3), and docosahexaenoic acid (DHA, 22:6n-3) have been shown to be cytotoxic to tumor cells. The objective of this work was to study the effects of PUFA on the radiation response of a 36B10 rat astrocytoma cell line. Supplementation of the astrocytoma cells with 15-45 microM GLA, EPA, or DHA produced marked changes in the fatty acid profiles of their phospholipids and neutral lipids. The methylene bridge index of these lipids increased significantly. These PUFA also exerted cytotoxic effects, as determined using the clonogenic cell survival assay. While GLA and DHA produced a moderate cell-killing effect, EPA was extremely cytotoxic, especially at a concentration of 45 microM. The monounsaturated oleic acid (OA, 18:1n-9) did not affect cell survival. Further, all three PUFA, and particularly GLA, increased the radiation-induced cell kill; OA did not enhance the effect of radiation. alpha-Tocopherol acetate blocked the enhanced radiation sensitivity of GLA- and DHA-supplemented cells. In conclusion, GLA, EPA, and DHA supplementation prior to, during, and after irradiation can enhance the radiation-induced cytotoxicity of rat astrocytoma cells. GLA and DHA supplementation post-irradiation also enhanced the radiation response of the 36B10 cells. Because GLA maximally increases the radioresponsiveness of a rat astrocytoma, this PUFA might prove useful in increasing the therapeutic efficacy of radiation in the treatment of certain gliomas.
Vartak
S
S
Department of Radiology, University of Iowa, Iowa City 52242, USA.
Robbins
M E
ME
Spector
A A
AA
D000818:Animals; D001254:Astrocytoma / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D002470:Cell Survival / Q000187:drug effects / Q000528:radiation effects; D004281:Docosahexaenoic Acids / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D015118:Eicosapentaenoic Acid / Q000494:pharmacology; D005227:Fatty Acids / Q000378:metabolism; D005231:Fatty Acids, Unsaturated / Q000378:metabolism / Q000494:pharmacology*; D050356:Lipid Metabolism; D019301:Oleic Acid / Q000494:pharmacology; D010743:Phospholipids / Q000378:metabolism; D011838:Radiation-Sensitizing Agents / Q000494:pharmacology*; D051381:Rats; D013997:Time Factors; D024505:Tocopherols; D014407:Tumor Cells, Cultured; D014810:Vitamin E / Q000031:analogs & derivatives / Q000494:pharmacology; D024502:alpha-Tocopherol / Q000031:analogs & derivatives*; D017965:gamma-Linolenic Acid / Q000494:pharmacology
D005227:Fatty Acids; D005231:Fatty Acids, Unsaturated; D010743:Phospholipids; D011838:Radiation-Sensitizing Agents; D014810:Vitamin E; D004281:Docosahexaenoic Acids; D019301:Oleic Acid; D017965:gamma-Linolenic Acid; D015118:Eicosapentaenoic Acid; D024502:alpha-Tocopherol; D024505:Tocopherols